18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
Not Applicable
Not yet recruiting
- Conditions
- 18F-HER2 PET
- Interventions
- Diagnostic Test: 18F-HER2 PET
- Registration Number
- NCT05983796
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Brief Summary
This is a open-label, one-arm, multicenter study aimed to explore the efficacy and safety of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Informed consent document must be signed.
- Aged 30-80 years old, both genders.
- Patients with locally advanced or advanced urothelial carcinoma
- Patients plan to undergo anti HER2 treatment.
Exclusion Criteria
- Subjects with active malignancies other than urothelial carcinoma within 5 years should be excluded.
- Patients with severe liver, kidney, and hematopoietic diseases
- Patients with other mental disorders or primary emotional disorders
- Those who are unable to understand, comply with the research protocol, or sign an informed consent form
- PET imaging Contraindication (including pregnant women, lactating women, women of childbearing age who have a recent fertility plan, etc.)
- Individuals who are allergic to imaging agents
- Hypoglycemic reactions, severe pain, etc. cannot be accompanied by PET scans
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 18F-HER2 PET 18F-HER2 PET -
- Primary Outcome Measures
Name Time Method Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma up to 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The First Affiliated Hospital, Zhejiang University School of medicine
🇨🇳Hangzhou, Zhejiang, China